Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending	Generic Name	Therapeutic Area	Recommendation Type	Project Status	Date Submission Received	Date Recommendation Issued
Avastin	Bevacizumab	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Nov 28, 2014	Jun 4, 2015
Avastin	Bevacizumab	Cervical Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 27, 2014	Mar 23, 2015
Avastin (with capecitabine)	Bevacizumab	Metastatic Colorectal Cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 18, 2015	Jul 21, 2015
Avodart	Dutasteride	Prostatic hyperplasia, benign	List in a similar manner to other drugs in class	Complete	Aug 24, 2004	Jan 20, 2005
Axert	Almotriptan	Migraine	List in a similar manner to other drugs in class	Complete	Dec 24, 2003	May 27, 2004
Azarga	Brinzolamide and timolol maleate suspension	Glaucoma and ocular hypertension	List in a similar manner to other drugs in class	Complete	Aug 28, 2009	Feb 18, 2010
Azilect	Rasagiline mesylate	Parkinson's disease	Do not list	Complete	Sep 1, 2006	Mar 28, 2007
Azilect	Rasagiline mesylate	Parkinson's disease	N/A	Complete	Mar 10, 2009
Banzel	Rufinamide	Lennox-Gastaut syndrome	List with clinical criteria and/or conditions	Complete	Sep 20, 2011	Mar 15, 2012
Baqsimi	glucagon	Severe hypoglycemic reactions	Reimburse with clinical criteria and/or conditions	Complete	Jul 24, 2019	Jan 22, 2020

Last Updated : June 2, 2023